학술논문
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis).
Document Type
Academic Journal
Author
Valenti M; Dermatology Unit, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni, 56, Rozzano, Milan, Italy. mario.valenti@hunimed.eu.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. mario.valenti@hunimed.eu.; Gargiulo L; Dermatology Unit, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni, 56, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Ibba L; Dermatology Unit, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni, 56, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Malagoli P; Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.; Amoruso F; Dermatology Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy.; Balato A; Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.; Bardazzi F; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy.; Burlando M; Department of Dermatology, Dipartimento di Scienze della Salute (DISSAL), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.; Carrera CG; Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122, Milan, Italy.; Dapavo P; Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy.; Dini V; Dermatology Unit, Department of Clinical and Experimental Medicine, Ospedale Santa Chiara, 11 Via Roma 67, 56126, Pisa, Italy.; Gaiani FM; Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.; Girolomoni G; Department of Medicine, Section of Dermatology and Venereology, University of Verona, Piazzale A. Stefani 1, 37126, Verona, Italy.; Guarneri C; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Unit of Dermatology, University of Messina, AOU Policlinico G. Martino, Via Consolare Valeria 1, 98125, Messina, Italy.; Lasagni C; Dermatological Clinic, Department of Specialized Medicine, University of Modena, Via del Pozzo 71, 41121, Modena, Italy.; Loconsole F; Department of Dermatology, University of Bari, Piazza Umberto I, 1, 70121, Bari, Italy.; Marzano AV; Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122, Milan, Italy.; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.; Maurelli M; Department of Medicine, Section of Dermatology and Venereology, University of Verona, Piazzale A. Stefani 1, 37126, Verona, Italy.; Megna M; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131, Naples, Italy.; Orsini D; UOC Clinical Dermatology-Dermatological Institute S. Gallicano, IRCCS, Rome, Italy.; Travaglini M; U.O.S.D. Dermatologica-Centro per la Cura della Psoriasi, Ospedale Perrino, Brindisi, Italy.; Costanzo A; Dermatology Unit, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni, 56, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Narcisi A; Dermatology Unit, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni, 56, Rozzano, Milan, Italy.
Source
Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2193-8210
Abstract
Introduction: The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safety in both clinical trials and real-world experiences. However, there is a lack of long-term real-world data available for ixekizumab.
Methods: We conducted a multicenter real-life study to evaluate the effectiveness and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis. Psoriasis Area and Severity Index score (PASI) was collected at baseline and after 1, 2, 3, 4, and 5 years. The occurrence of any adverse events was recorded at each time point.
Results: We enrolled 1096 patients treated with ixekizumab for at least 1 year. At week 52, the percentages of PASI 90 and PASI 100 were 85.04% and 69.07%, respectively. After 5 years of treatment with ixekizumab, out of 145 patients, a PASI 90 response was achieved by 86.90% of patients, while complete skin clearance was reached by 68.28% of patients. We did not observe any new significant safety findings throughout the study period.
Conclusion: This study supports the long-term effectiveness and safety of ixekizumab in a real-world setting.
(© 2024. The Author(s).)
Methods: We conducted a multicenter real-life study to evaluate the effectiveness and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis. Psoriasis Area and Severity Index score (PASI) was collected at baseline and after 1, 2, 3, 4, and 5 years. The occurrence of any adverse events was recorded at each time point.
Results: We enrolled 1096 patients treated with ixekizumab for at least 1 year. At week 52, the percentages of PASI 90 and PASI 100 were 85.04% and 69.07%, respectively. After 5 years of treatment with ixekizumab, out of 145 patients, a PASI 90 response was achieved by 86.90% of patients, while complete skin clearance was reached by 68.28% of patients. We did not observe any new significant safety findings throughout the study period.
Conclusion: This study supports the long-term effectiveness and safety of ixekizumab in a real-world setting.
(© 2024. The Author(s).)